Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors

INTRODUCTION AND OBJECTIVE: Polymorphisms in genes encoding drug metabolizing enzymes may lead to varied enzyme activity and inter-individual variability in drug efficacy and/or toxicity. Since CYP2C19 and CYP3A4 genes code for enzymes involved in metabolizing wide variety of drugs including proton...

Descripción completa

Detalles Bibliográficos
Autores principales: Deshpande, Neha, V., Sharanya, V. V., Ravi Kanth, H. V. V., Murthy, M., Sasikala, Banerjee, Rupa, Tandan, Manu, D., Nageshwar Reddy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932617/
https://www.ncbi.nlm.nih.gov/pubmed/27419077
http://dx.doi.org/10.1016/j.mgene.2016.06.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932617/
https://www.ncbi.nlm.nih.gov/pubmed/27419077
http://dx.doi.org/10.1016/j.mgene.2016.06.004

Ejemplares similares